These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 10190945)

  • 1. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
    N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
    Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
    Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
    Gonzalez H; Leblond V; Azar N; Sutton L; Gabarre J; Binet JL; Vernant JP; Dighiero G
    Hematol Cell Ther; 1998 Jun; 40(3):113-8. PubMed ID: 9698219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity.
    Spriano M; Clavio M; Carrara P; Canepa L; Miglino M; Pierri I; Celesti L; Rossi E; Vimercati R; Bruni R
    Haematologica; 1994; 79(3):218-24. PubMed ID: 7926970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Martell RE; Peterson BL; Cohen HJ; Petros WP; Rai KR; Morrison VA; Elias L; Shepherd L; Hines J; Larson RA; Schiffer CA; Hurwitz HI
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):37-45. PubMed ID: 12111110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia.
    Zinzani PL; Bendandi M; Magagnoli M; Albertini P; Rondelli D; Stefoni V; Tani M; Tura S
    Haematologica; 2000 Nov; 85(11):1135-9. PubMed ID: 11064464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R
    Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.